Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors
Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced solid tumors.
Advanced Solid Tumors
DRUG: SP-2577 Seclidemstat
Safety and tolerability of SP-2577, Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, From screening through at least 30 days after end of treatment, up to approximately 24 months
Determine the maximum tolerated dose of SP-2577, Defined as the dose level immediately below the dose level at which â‰¥ 2 patients from a cohort of 3 to 6 patients experience a dose-limiting toxicity (DLT)., DLTs within the first cycle of therapy (up to 28 days)|Characterization of pharmacokinetics of SP-2577 (area under the concentration time profile), SP-2577 under fasted and fed conditions, At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.|Characterization of pharmacokinetics of SP-2577 (time to maximum plasma concentration), SP-2577 under fasted and fed conditions, At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.|Characterization of pharmacokinetics of SP-2577 (maximum plasma concentration), SP-2577 under fasted and fed conditions, At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.|Characterization of pharmacokinetics of SP-2577 (half-life), SP-2577 under fasted and fed conditions, At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.|Characterization of pharmacokinetics of SP-2577 (clearance rate), SP-2577 under fasted and fed conditions, At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.|Characterization of pharmacokinetics of SP-2577 (volume of distribution), SP-2577 under fasted and fed conditions, At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.|Efficacy parameter: overall response rate of SP-2577, Assessed by radiographic imaging with response and progression evaluated by RECIST 1.1 guidelines, From start of treatment through at least 30 days after end of treatment, up to approximately 24 months|Efficacy parameter: duration of response of SP-2577, Assessed by radiographic imaging with response and progression evaluated by RECIST 1.1 guidelines, From start of treatment through at least 30 days after end of treatment, up to approximately 24 months|Efficacy parameter: progression-free survival of SP-2577, Assessed by radiographic imaging with response and progression evaluated by RECIST 1.1 guidelines, From start of treatment through at least 30 days after end of treatment, up to approximately 24 months|Changes in serum hemoglobin F concentrations, Determine changes serum hemoglobin F concentrations correlated with SP-2577 treatment and clinical and radiographic markers of disease burden (either response or resistance/progression)., At protocol defined time points from start of treatment through end of treatment, up to approximately 24 months|Changes in the molecular signatures of the tumor, Assessed in dose expansion only by RNA-seq testing of tumor biopsy samples to determine changes in gene expression patterns by SP-2577 treatment to elucidate biological changes induced in the tumor by LSD1 inhibition., At protocol defined time points from start of treatment through end of treatment, up to approximately 24 months
Phase 1, open-label, non-randomized dose finding study of SP-2577 given as oral tablets in patients with advanced solid tumors in 28-day cycles. The study design is based on a Simon's 4B design without intrapatient dose escalation.